BioCentury | May 21, 2020
Emerging Company Profile

Repertoire bets on both sides of the TCR-antigen coin

Flagship’s Repertoire aims to identify which TCRs and antigens matter in disease and apply those insights to biomarkers and therapies, starting with a cytokine-loaded T cell candidate for cancer. Repertoire Immune Medicines Inc. emerged in...
BC Extra | Sep 6, 2019
Preclinical News

Neon improves predictions for CD4-stimulating tumor antigens

In the latest step toward breaking the barrier to identifying neoantigens displayed on MHCII, Neon has generated a systems biology model that outperforms publicly available predictors. The development brings immuno-oncology closer to personalized therapies directing...
BC Innovations | Jun 20, 2019
Distillery Therapeutics

MHCII nanoparticles for autoimmune hepatic diseases

DISEASE CATEGORY: Hepatic INDICATION: Cirrhosis; hepatitis; liver disease A team led by Parvus Therapeutics Inc. founder Pere Santamaria has developed nanoparticles coated with MHCII molecules displaying a PDH-derived epitope associated with primary biliary cholangitis (PBC)...
BC Extra | Mar 26, 2019
Company News

Sana adds hypoimmunogenic stem cell tech from Harvard to its tool kit

Building out its portfolio of cell and gene therapy tools, Sana licensed technology from Harvard University comprising methods to create stem cells that avoid triggering immune rejection when transplanted. The hypoimmunogenic stem cells are derived...
BC Innovations | Feb 26, 2019
Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for making iPS cells hypoimmunogenic could be used to generate allogeneic cell grafts for transplant therapies. The method involves two to three steps: simultaneous or sequential CRISPR-Cas9 (CRISPR-associated protein 9)-mediated...
BC Extra | Feb 20, 2019
Preclinical News

Engineering allogeneic iPS cells to avoid transplant rejection

UCSF researchers have made headway toward developing universal allogeneic iPS cell therapies by identifying a dual mechanism that prevented immune rejection in mice. Adult stem cells have shown limited efficacy as a regenerative strategy for...
BC Innovations | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BC Innovations | Dec 11, 2018
Translation in Brief

Diseased oligodendrocytes

A Karolinska Institute team has identified subsets of oligodendrocyte lineage cells that may trigger T cell immunity in multiple sclerosis and proposed the cells as new disease targets. The findings suggest the myelin-producing cells are...
BC Week In Review | Jun 29, 2018
Clinical News

Immutep reports ORR data for eftilagimod plus Keytruda in Phase I for melanoma

Immutep Ltd. (ASX:IMM; NASDAQ:IMMP) said eftilagimod alpha (IMP321) plus PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) led to a best overall response rate (ORR) of 61% in 18 previously treated patients with...
BC Innovations | Jun 14, 2018
Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
Items per page:
1 - 10 of 134